论文部分内容阅读
目的探讨比索洛尔对抗β1-肾上腺素能受体(β1-AR)自身抗体阳性心衰大鼠心功能的影响。方法采用缩窄腹主动脉的方法,建立慢性心力衰竭的大鼠模型。将心衰组大鼠(90只最终入组65只)随机分为心衰治疗组(40只)和心衰非治疗组(25只)。心衰治疗组接受比索洛尔4周的治疗。心衰非治疗组接受同剂量的蒸馏水同样时间的治疗。应用ELISA法检测大鼠血清β1-AR自身抗体的阳性率和滴度;应用BL-420E生物机能实验系统于治疗前及治疗后4周检测心功能。结果①治疗组组内抗β1-AR自身抗体阳性者较阴性者左室舒张末压低,左室变化的最大速率升高,但无统计学意义;非治疗组组内抗β1-AR自身抗体阳性者较阴性大鼠的心功能进一步恶化,左室舒张末压明显升高(P<0.01),左室变化的最大速率下降(P<0.05)。②治疗组中抗β1-AR自身抗体阳性者与非治疗组中抗β1-AR自身抗体阳性者比较,前者较后者左室舒张末压明显下降(P<0.01);左室变化的最大速率均显著升高(P<0.05)。结论比索洛尔治疗后,心衰大鼠抗β1-AR自身抗体阳性者的心功能较非治疗组中抗β1-AR自身抗体阳性者的心功能明显改善。同为治疗组的抗β1-AR自身抗体阳性者的心功能较阴性者的左室舒张末压低,左室变化的最大速率升高。
Objective To investigate the effect of bisoprolol on cardiac function in β1-adrenergic receptor-positive heart failure rats. Methods The method of narrowing the abdominal aorta was used to establish a rat model of chronic heart failure. The heart failure rats (90 of the final group of 65) were randomly divided into heart failure treatment group (40) and non-treatment of heart failure group (25). Heart failure treatment group received 4 weeks of bisoprolol treatment. Non-treatment of heart failure patients receive the same dose of distilled water for the same treatment. Serum β1-AR autoantibodies were detected by ELISA. The BL-420E bio-functional assay system was used to detect cardiac function before treatment and 4 weeks after treatment. Results ① The anti-β1-AR autoantibodies in the treatment group were significantly lower than those in the negative ones and the maximum rate of left ventricular changes was not statistically significant. The anti-β1-AR autoantibodies in the untreated group were positive Compared with negative rats, heart function was further worsened, left ventricular end diastolic pressure was significantly increased (P <0.01), the maximum rate of left ventricular changes was decreased (P <0.05). ② The anti-β1-AR autoantibodies in the treatment group were significantly lower than the anti-β1-AR autoantibodies in the non-treatment group (P <0.01); the maximum rate of left ventricular change Were significantly higher (P <0.05). Conclusion After bisoprolol treatment, the cardiac function of anti-β1-AR autoantibody-positive patients with heart failure was significantly improved compared with that of non-treated patients with anti-β1-AR autoantibody. The same as the treatment group anti-β1-AR autoantibody-positive cardiac function than negative LV end-diastolic pressure, the maximum rate of left ventricular changes increased.